Teva Pharmaceutical Industries (NYSE:TEVA) Stock Gets Price Target Increase from TD Cowen

Teva Pharmaceutical Industries (NYSE:TEVA) had its price target boosted by research analysts at TD Cowen from $55.00 to $57.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. TD Cowen‘s price target would indicate a potential upside of 35.72% from the stock’s current price.

A number of other research firms also recently weighed in on TEVA. Leerink Partners assumed coverage on Teva Pharmaceutical Industries in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 target price for the company. UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a research note on Friday, September 4th. Oppenheimer boosted their target price on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, October 9th. Weiss Ratings upgraded shares of Teva Pharmaceutical Industries from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Finally, Piper Sandler lifted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 28th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $46.69.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock traded up $0.09 during mid-day trading on Wednesday, hitting $42.00. 5,660,564 shares of the company were exchanged, compared to its average volume of 6,797,240. Teva Pharmaceutical Industries has a 12-month low of $22.70 and a 12-month high of $43.34. The company has a market capitalization of $48.94 billion, a P/E ratio of 69.79, a PEG ratio of 3.77 and a beta of 0.97. The business’s 50 day simple moving average is $39.24 and its two-hundred day simple moving average is $34.64. The company has a debt-to-equity ratio of 1.56, a current ratio of 0.88 and a quick ratio of 0.67.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.14. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. The business had revenue of $4.39 billion during the quarter, compared to the consensus estimate of $4.23 billion. During the same period in the prior year, the firm posted $0.78 EPS. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. Analysts forecast that Teva Pharmaceutical Industries will post 2.00 earnings per share for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 367,600 shares of the business’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $39.06, for a total transaction of $14,358,456.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Brian Savage sold 7,342 shares of the firm’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $38.85, for a total transaction of $285,236.70. Following the transaction, the insider directly owned 8,500 shares of the company’s stock, valued at $330,225. The trade was a 46.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.54% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Harel Insurance Investments & Financial Services Ltd. raised its stake in shares of Teva Pharmaceutical Industries by 2.2% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 45,956,714 shares of the company’s stock worth $1,384,216,000 after purchasing an additional 1,004,941 shares during the last quarter. WCM Investment Management LLC boosted its stake in Teva Pharmaceutical Industries by 191.4% in the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock valued at $1,157,264,000 after acquiring an additional 26,813,522 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Teva Pharmaceutical Industries by 5.8% during the second quarter. Wellington Management Group LLP now owns 7,671,157 shares of the company’s stock valued at $259,899,000 after purchasing an additional 419,329 shares during the last quarter. Janus Henderson Group PLC raised its holdings in Teva Pharmaceutical Industries by 1.5% during the 1st quarter. Janus Henderson Group PLC now owns 4,816,657 shares of the company’s stock valued at $145,076,000 after acquiring an additional 72,880 shares during the period. Finally, Bessemer Group Inc. boosted its position in shares of Teva Pharmaceutical Industries by 1.6% in the first quarter. Bessemer Group Inc. now owns 4,350,483 shares of the company’s stock valued at $131,036,000 after acquiring an additional 70,058 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

More Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva reported Q3 adjusted EPS of $0.86, above the $0.72 analyst consensus, and revenue of about $4.39 billion, topping estimates of $4.23 billion. The earnings beat and stronger branded-drug sales helped prompt higher 2026 revenue and product-sales guidance. Teva Q3 earnings beat and guidance raised
• Positive Sentiment: UZEDY, Teva’s long-acting schizophrenia treatment, generated $85 million in U.S. Q3 sales, up 96% year over year. Teva raised its 2026 UZEDY revenue outlook to $290–$310 million from $270–$290 million, providing evidence of momentum in its growth portfolio. UZEDY sales and outlook
• Positive Sentiment: A deal with Samsung Bioepis gives Teva U.S. commercialization rights to two FDA-approved biosimilars, expanding its immunology portfolio and potentially adding future revenue. Teva and Samsung Bioepis agreement
• Positive Sentiment: Management expects growth to accelerate in 2027 despite U.S. Inflation Reduction Act pressure on Austedo, suggesting confidence in the broader business and newer products. Teva outlook for 2027
• Negative Sentiment: Q3 revenue was down 1.9% year over year, reflecting pressure including generic-drug declines. Teva also ended its Phase 2 TOPAS-MSA study of emrusolmin after an interim analysis indicated a low likelihood of meeting the efficacy target. The decision removes a potential pipeline opportunity, although no safety concerns were identified. Teva discontinues emrusolmin trial

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world’s largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva’s portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.